“
TL;DR
This economic modeling study found that among antiobesity drugs approved for adolescents with severe obesity, phentermine-topiramate was the most cost-effective treatment option.
JAMA Network Open · 2 authors, 2 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This economic modeling study found that among antiobesity drugs approved for adolescents with severe obesity, phentermine-topiramate was the most cost-effective treatment option.
The primary outcome was the incremental cost per quality-adjusted life-year (QALY) gained. The analysis used a 10-year time horizon. The study was limited by reliance on 1-year weight loss data from clinical trials and the lack of long-term efficacy data. Findings suggest phentermine-topiramate offers good value for money for payers, though the budgetary impact of widespread use remains substantial.